Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Gilead Sciences, Inc. and Novartis Pharmaceuticals Corporation.

Community Practice Connections™: Integrating CAR T-Cell Therapy for the Treatment of Lymphoid Malignancies: What the Community Oncologist Needs to Know

Release Date: July 31, 2019
Expiration Date: July 31, 2020
Media: Internet - based

Activity Overview

Community Practice Connections™: Integrating CAR T-Cell Therapy for the Treatment of Lymphoid Malignancies: What the Community Oncologist Needs To Know provides case-based discussion of clinical data on the use of chimeric antigen receptor (CAR) T cells in patients with lymphoid malignancies, with a focus on acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). Interactive clinical vignettes are followed by short video interviews with leading experts in the management of patients with ALL and DLBCL. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting by healthcare professionals utilizing CAR T-cell therapy for patients with lymphoid malignancies.

Benefits of Participating

  • Gain insights into the unique properties of CAR T-cell therapy relative to other therapeutic modalities
  • Evaluate clinical trial data on CAR T cells in patients with relapsed/refractory hematologic malignancies
  • Learn about management strategies for cytokine release syndrome and neurotoxicity associated with CAR T-cell therapy
  • Recognize the importance of long-term monitoring of patients who undergo CAR T-cell therapy

Acknowledgement of Commercial Support

This activity is supported by educational grants from Gilead Sciences, Inc. and Novartis Pharmaceuticals Corporation.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video files/content until you finish the presentation.
  • At the end of the activity, educational content/video files will be available for your reference.
  • In order to receive a CME/CE certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This educational activity is directed toward community oncologists and hematologists who treat patients with lymphoid malignancies. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of lymphoid malignancies will also be invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Recognize the unique mechanism of CAR T-cell action and the nuances of the manufacture of CAR T-cell therapy
  • Evaluate clinical trial data in the context of CAR T-cell therapy and its place in evolving hematologic malignancy treatment paradigms
  • Explain pathways for the use of CAR T cells, including identification of eligible patients, process of referral to the treatment centers, and the importance of posttreatment follow-up
  • Determine the potential CAR T-cell treatment-related toxicities and best practices for adverse event detection, grading, monitoring, management, and mitigation

Faculty, Staff, and Planners’ Disclosures


Cameron Turtle
Cameron Turtle, MBBS, PhD, FRACP, FRCPA
Attending Physician
Fred Hutch Bone Marrow Transplant Program &
Seattle Cancer
Care Alliance Immunotherapy Service
Seattle, WA

Disclosures: Grant/Research Support: Juno Therapeutics, Nektar Therapeutics; Consultant: Allogene, Eureka Therapeutics, Caribou Biosciences, Kite/Gilead, Nektar Therapeutics, Novartis, Precision Biosciences, T-CX; Stock/Shareholder: Caribou Biosciences, Eureka Therapeutics, Precision Biosciences; Ad Board: Humanigen.

Jae Hong Park
Jae Hong Park, MD
Associate Attending Physician
Department of Medicine, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant/Research Support: Genentech, Juno Therapeutics, Amgen, Servier, Incyte; Consultant: Amgen, Novartis, Kite Pharma, AstraZeneca, Incyte, Takeda, Allogene.

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER® or any of the companies that provided commercial support for this program.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By